Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

vituximab toward later-stage clinical trials. Planning for this exciting next phase for our bavituximab oncology program has already begun."

Mr. King added, "This past year we also made significant advancements in our bavituximab and broader anti-PS anti-viral program, receiving high-profile international validation through the publication of data in the highly respected scientific journal Nature Medicine, which confirmed the anti-viral potential of bavituximab and our other anti-PS antibodies. We were also successful in completing contract negotiations with the DTRA, allowing us to expand the evaluation of our anti-PS antibodies as potential broad spectrum agents for the treatment or prevention of viral hemorrhagic fever virus infections. This contract directly or indirectly supports our bavituximab and other anti-PS technology programs and represents another significant validation for the anti-PS technology platform."

Mr. King continued, "Our Cotara clinical program continues to advance with patient enrollment nearing completion in our dose confirmation and dosimetry study in patients with recurrent glioblastoma (GBM), and enrollment exceeds the halfway mark in our Phase II trial in relapsed GBM patients. We recently presented dosimetry study data at the Society of Nuclear Medicine 2009 Annual Meeting, further confirming that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs, reinforcing its potential as a possible new treatment for GBM."

At April 30, 2009, Peregrine had $10 million in cash and cash equivalents, compared to $15.1 million in cash and cash equivalents at April 30, 2008. After the close of the 2009 fiscal year, Peregrine raised approximately $6.9 million in gross proceeds from the sale of common stock from its existing shelf registration. The stock was sold in an "At the Market" offering as defined in Rule 415
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Speaking on this occasion, ... observed ‘Nursing Conference’ as a remarkable event, which brings ... medical and clinical research and diagnostic companies, leading universities ... a perfect platform to share experience, foster collaborations across ... world. Nursing Conference is a forum to explore issues ...
(Date:9/30/2014)... New Zealand (PRWEB) September 30, 2014 ... the potential to improve breast cancer risk prediction ... according to a study published in Breast Cancer ... “Digital mammographic density and breast cancer risk: a ... demonstrates a strong connection between breast density and ...
(Date:9/30/2014)... and its partners successfully established a visual mapping ... myeloid derived suppressor cells (MDSC). The damage and ... understood, however this is a major stepping stone ... by tumor-derived factors from precursors present in hematopoietic ... spleen. This population of cells suppresses the activity ...
(Date:9/30/2014)... A recent study completed at the University of Eastern ... the risk of coronary heart disease. The sources of ... The findings were published in Arteriosclerosis, Thrombosis & ... Heart Association. , Recent studies have not found an ... risk of cardiovascular diseases. It seems that the mere ...
(Date:9/30/2014)... 2014 This two-day, advanced PT ... sequellae that may arise following a concussion or ... can be varied, from sports related injuries, car accidents, ... by the thousands of returning soldiers from war zone ... and blunt traumas can result in similar injuries, the ...
Breaking Medicine News(10 mins):Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:Dietary polyunsaturated fatty acids linked to smaller risk of coronary heart disease 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3
... Minn. People with a particular gene variant may be more ... people without the gene, according to a study published in the ... journal of the American Academy of Neurology. , The ... no cancers. All those with tumors had glioblastoma multiforme, the most ...
... when they spend any timeeven a few monthswithout health care ... 2009 issue of Medical Care Research and Review . ... four months, there is a 2.8 percentage point decrease in ... the study, Partial-Year Insurance Coverage and the Health Care Utilization ...
... other experts sponsor workshop to investigate increase in Acanthamoeba ... contact lens care products and protect against infectionsST. LOUIS, ... safety and effectiveness of contact lenses and lens care ... Optometric Association (AOA) co-sponsored a workshop last week with ...
... of batches tested positive, third of popular sweetened products ... Almost half of tested samples of commercial high-fructose corn ... nearly a third of 55 popular brand-name food and ... labeled ingredient, according to two new U.S. studies. , ...
... AFL ) announced today that it will release ... 2, 2009. , In conjunction ... meeting on Tuesday, February 3, 2009. During the ... discuss Aflac,s fourth,quarter and year-end results. Following Mr. Amos, ...
... of cases, study finds , , MONDAY, Jan. 26 ... the United States are more likely than girls ... at football, soccer, volleyball, basketball, wrestling, baseball and ... 8 percent of all injuries suffered by high ...
Cached Medicine News:Health News:New study: Short coverage lapses limit children's access to health care services 2Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 2Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 3Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 4Health News:AOA Doctors of Optometry Partner With FDA and Other Industry Leaders to Develop New Measures to Better Protect Contact Lens Wearers 5Health News:Study Finds High-Fructose Corn Syrup Contains Mercury 2Health News:Aflac Incorporated To Release Fourth Quarter Results on February 2, 2009 2Health News:HS Sports Shoulder Injuries More Likely in Boys 2
(Date:9/30/2014)... , Sept. 30, 2014 Headquartered in ... GWPC) is a diversified company comprised of several specialized ... advanced technology and the proven expertise of its team ... and wellness. WholeHealth Products, line of more than 10 ... centers, and its more than 8 retail consumer tests ...
(Date:9/30/2014)... N.Y. , Sept. 30, 2014  Millennium ... Millennium Medical Devices, has executed a sales, marketing ... Florida based provider of ... Accountable Care Organizations (ACOs) and hospitals through a ... serves over 10,400 active Physician Purchasing Accounts that ...
(Date:9/30/2014)...  The Corporate Whistleblower Center is urging ER ... 866-714-6466 if they have well documented proof of ... been sent home, as an intentional way to ... as the Center would like to explain. ... Photo - http://photos.prnewswire.com/prnh/20140929/149017 ...
Breaking Medicine Technology:WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 2Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 2Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 4
... 16 The board of directors of Intarcia Therapeutics, ... Kurt Graves as executive chairman of the board. In ... leadership to the board and work closely with management ... development with its potential blockbuster asset, ITCA 650 (DUROS® ...
... ONXX ) today announced that it will present ... 22, 2010 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific ... of the presentation on our website at: ... on 15 minutes early in order to register and download ...
Cached Medicine Technology:Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals 2Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals 3Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference 2
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
... and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: